Targeting EGFL7 Expression through RNA Interference Suppresses Renal Cell Carcinoma Growth by Inhibiting Angiogenesis |
Xu, Han-Feng
(Department of Urology, Shengjing Hospital of China Medical University)
Chen, Lei (Department of Surgery, Hunan Polytechnic of Environment and Biology) Liu, Xian-Dong (Department of Urology, Shengjing Hospital of China Medical University) Zhan, Yun-Hong (Department of Urology, Shengjing Hospital of China Medical University) Zhang, Hui-Hui (Department of Urology, First Affiliated Hospital of Nanhua University) Li, Qing (Department of Urology, First Affiliated Hospital of Nanhua University) Wu, Bin (Department of Urology, Shengjing Hospital of China Medical University) |
1 | Wu F, Yang LY, Li YF, et al (2009). Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology, 50, 1839-50. DOI ScienceOn |
2 | Sun Y, Bai Y, Zhang F, et al (2010). miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun, 391, 1483-9. DOI ScienceOn |
3 | Tanriverdi O (2013). Review on targeted treatment of patients with advanced-stage renal cell carcinoma: a medical oncologist's perspective. Asian Pac J Cancer Prev, 14, 609-17. DOI ScienceOn |
4 | Weis SM, Cheresh DA (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med, 17, 1359-70. DOI ScienceOn |
5 | Grunwald V, Ravaud A (2014). Systemic therapy of renal cell carcinoma. World J Urol, 32, 1. DOI ScienceOn |
6 | Diaz R, Silva J, Garcia JM, et al (2008). Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer, 47, 794-802. DOI ScienceOn |
7 | Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmannh (2004). Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn, 230, 316-24. DOI ScienceOn |
8 | Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8. DOI |
9 | Huang CH, Li XJ, Zhou YZ, et al (2010). Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol, 136, 1737-43. DOI |
10 | Nikolic I, Stankovic ND, Bicker F, et al (2013). EGFL7 ligates alphavbeta3 integrin to enhance vessel formation. Blood, 121, 3041-50. DOI ScienceOn |
11 | Parker LH, Schmidt M, Jin SW, et al (2004). The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature, 428, 754-8. DOI ScienceOn |
12 | Rini BI, Campbell SC, Escudier B (2009). Renal cell carcinoma. Lancet, 373, 1119-32. DOI ScienceOn |
13 | Schmidt M, Paes K, De Maziere A, et al (2007). EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development, 134, 2913-23. DOI ScienceOn |
14 | Shojaei F (2012). Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett, 320, 130-7. DOI ScienceOn |
15 | Sieg DJ, Hauck CR, Ilic D, et al (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2, 249-56. DOI ScienceOn |
16 | Carmeliet P, Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307. DOI ScienceOn |
17 | Cairns P (2010). Renal cell carcinoma. Cancer Biomark, 9, 461-73. |
18 | Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-57. DOI ScienceOn |
19 | Chung AS, Lee J, Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer, 10, 505-14. DOI ScienceOn |
20 | Cohen HT, McGovern FJ (2005). Renal-cell carcinoma. N Engl J Med, 353, 2477-90. DOI ScienceOn |
21 | Campagnolo L, Leahy A, Chitnis S, et al (2005). EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol, 167, 275-84. DOI ScienceOn |